NOTCH4 and breast cancer: We have shown for the first time, to our knowledge, that PEA3 is a novel activator of Notch-1 and Notch-4 transcription in different subtypes of breast cancer cells and could prove to be an important therapeutic target, possibly upstream of Notch-1 and/or Notch-4 signaling.